The Treat FTD Fund
Forecasted
The Treat FTD Fund supports early-stage clinical trials for innovative FTD treatments, prioritizing biomarker integration and novel trial designs, funded by The Association for Frontotemporal Degeneration.
Funder: The Association for Frontotemporal Degeneration
Due Dates (Anticipated): November 2026 (Letter of Intent) | February 2027 (Full Application)
Funding Amounts: Up to $2,500,000 per project; typical range $500,000–$2,500,000 over 1–3 years.
Summary: Supports early-stage clinical trials for innovative treatments targeting frontotemporal degeneration, with emphasis on biomarker integration and rare disease trial design.
Key Information: This is a forecasted grant; all dates are projected and subject to change.
Description
The Treat FTD Fund, established by The Association for Frontotemporal Degeneration (AFTD) in partnership with the Alzheimer’s Drug Discovery Foundation (ADDF), is dedicated to accelerating the development of effective therapies for frontotemporal degeneration (FTD) disorders. The fund supports early-stage clinical trials that leverage advances in understanding FTD’s biological mechanisms, prioritize the integration of biomarkers for target engagement and pharmacologic effects, and employ innovative trial designs suitable for rare diseases. Projects may focus on disease-modifying or symptomatic treatments, including experimental drugs, repurposed medications, gene therapies, antibodies, ASOs, and non-pharmacologic interventions such as devices. Collaboration with clinical networks and leveraging of existing resources are highly encouraged to maximize impact and accelerate clinical translation.
